EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Does BRAF mutation status and related clinicopathological factors affect the recurrence rate of ameloblastoma? A systematic review, meta‐analysis and metaregression

Ashutosh Kumar Singh iD, Ragavi Alagarsamy, Rajib Chaulagain iD, Abanish Singh iD, Dipak Sapkota iD, Selvam Thavaraj iD, Rabindra P Singh

Journal of Oral Pathology & Medicine · 2023

DOI: 10.1111/jop.13494 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of Oral Pathology & Medicine, 2023. Verfasst von Ashutosh Kumar Singh und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral and Maxillofacial Surgery, Maharajgunj Medical Campus, Institute of Medicine, Tribhuvan University Teaching Hospital, Kathmandu, N…. Hauptthemen laut MEDLINE: Ameloblastoma. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

This review aims to analyse the recurrence rate in BRAFv600e + and BRAFv600e − ameloblastomas and explore its association with clinicopathological variables.

Methods

A comprehensive search was conducted using databases including PubMed, Embase, Cochrane Central Register of Controlled Trials, Clinicaltrials.gov , Google Scholar and grey literature, without any limitation on start date or language up to 20 June 2023. A random effect meta‐analysis was conducted and Metaregression analyses were performed based on available clinicopathological factors.

Results

Fifteen studies met the criteria for meta‐analysis of outcomes. There was no significant difference in overall recurrence rates between the two groups (risk difference = 0.001, p ‐value = 0.987). Increasing male:female ratio in the BRAFv600e + group was associated with a lower reported recurrence, suggesting a higher recurrence rate in females. The odds of having mandibular lesion were four times higher in BRAFv600e + cases compared to BRAFv600e − cases (confidence interval: 2.121–7.870, p < 0.001, I 2 = 28.37%).

Conclusion

Within the BRAFv600e + group, females showed a higher reported recurrence rate. This specific clinical group may benefit from BRAFv600e mutation investigation and potential upscaled surgical treatment and additional BRAF inhibitor therapy, which needs validation in future studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AmeloblastomaHumansMaleFemaleProto-Oncogene Proteins B-rafMutationMolecular Targeted Therapy

Stichwörter der Autor:innen

BRAF mutationameloblastomaimmunotherapyjaw tumour

Substanzen

Proto-Oncogene Proteins B-rafBRAF protein, human

Autor:innen und Institutionen

  • Department of Oral and Maxillofacial Surgery, Maharajgunj Medical Campus, Institute of Medicine, Tribhuvan University Teaching Hospital, Kathmandu, Nepal.
  • Department of Burns, Plastic and Maxillofacial Surgery, Safdarjung Hospital, New Delhi, India.
  • Department of Oral Biology, Chitwan Medical College, Bharatpur, Nepal.
  • Department of Community Dentistry, National Medical College, Birgunj, Nepal.
  • Department of Oral Biology, Faculty of Dentistry, University of Oslo, Oslo, Norway.
  • Department of Oral Pathology, Guy's Hospital, London, UK.

ORCID-Profile: Ashutosh Kumar Singh, Rajib Chaulagain, Abanish Singh, Dipak Sapkota, Selvam Thavaraj

Zitieren

APA

Singh, A. K., Alagarsamy, R., Chaulagain, R., Singh, A., Sapkota, D., Thavaraj, S., & Singh, R. P. (2023). Does BRAF mutation status and related clinicopathological factors affect the recurrence rate of ameloblastoma? A systematic review, meta‐analysis and metaregression. Journal of Oral Pathology & Medicine. https://doi.org/10.1111/jop.13494

Vancouver

Singh AK, Alagarsamy R, Chaulagain R, Singh A, Sapkota D, Thavaraj S, et al. Does BRAF mutation status and related clinicopathological factors affect the recurrence rate of ameloblastoma? A systematic review, meta‐analysis and metaregression. Journal of Oral Pathology & Medicine. 2023. doi:10.1111/jop.13494

BibTeX
@article{Singh2023,
  author = {Singh, Ashutosh Kumar and Alagarsamy, Ragavi and Chaulagain, Rajib and Singh, Abanish and Sapkota, Dipak and Thavaraj, Selvam and Singh, Rabindra P},
  title = {Does BRAF mutation status and related clinicopathological factors affect the recurrence rate of ameloblastoma? A systematic review, meta‐analysis and metaregression},
  journal = {Journal of Oral Pathology & Medicine},
  year = {2023},
  doi = {10.1111/jop.13494}
}
Kostenlos starten →